print this page

Clinical Trials: Mental Health


MEM-MD 91 An Open-label study of the safety and tolerability of Memantine in Pediatric patients(6-12 y.o.) with Autism, AspergersDisorder or Pervasive Deveopmental Disorder Not otherwise Specified. (IRB# 338277-11)

(Children's health, Mental health)
  • Principal Investor
    Bruce Waslick, MD
  • Summary

    The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).  

  • More Information

    Eligibility

    Must be between the ages of 6-12 and meet the criteria for diagnosis of autism, Asperger’s Disorder or Pervasive Developmental Disorder not otherwise specified.  

  • Study Site Location
    3300 Main Street, Springfield, MA
  • Contact
    Julie Kingsbury
    413.794.1136
    Email